By the Top Tier Newswire AI Desk · July 21, 2026 at 5:08 AM ET · reviewed against 2 wire stories
PERSONALIS INC (PSNL) is drawing unusual attention today. Our newswire has captured 2 stories on PSNL across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 48/100).
Why PSNL stock is moving today
Personalis Inc. (PSNL) shares are moving sharply lower today, down approximately 10% as of the latest data. The stock is reacting to a definitive merger agreement announced by Tempus AI, Inc. to acquire Personalis in an all-stock deal valued at $1.5 billion. The deal is expected to strengthen Tempus AI’s precision oncology business but has triggered immediate market skepticism, with both PSNL and TEM shares falling.
What Happened
On July 20, 2026, Tempus AI, Inc. announced a definitive merger agreement to acquire Personalis. The deal is intended to enhance Tempus AI’s position in minimal residual disease (MRD) testing and expand its biopharma data capabilities. The merger was detailed in a published slide deck and discussed in an M&A call with investors. However, the market has responded negatively, with Tempus AI shares falling about 8% and Personalis shares declining in tandem.
Analysts have offered mixed reactions. Needham cut Personalis’ stock rating, while Morgan Stanley expressed cautious optimism about the strategic value of the acquisition. Retail traders on social media platforms are also discussing the deal, with some calling the price per share of $16.25 a potential floor for the stock.
What The Data Shows
Personalis has a market cap of $1.6 billion and is currently unprofitable, with a trailing twelve-month (TTM) earnings per share (EPS) of -1.02 and revenue declining by 24.7% TTM. The stock has traded between $3.84 and $16.39 over the past 52 weeks. Recent insider activity has also been bearish, with eight insider sales totaling $7.1 million in the last 90 days, the most recent on July 15. The stock is also trading with a beta of 2.24, indicating high volatility relative to the broader market.
What To Watch
Personalis is not scheduled to report earnings in the near term. Investors should monitor the breadth of analyst coverage and any changes in the stock rating from key firms like Needham and BTIG. Additionally, the market’s reaction to the merger’s integration progress and long-term strategic value will be crucial to the stock’s performance.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.